[go: up one dir, main page]

WO2009008666A3 - Autologous dendritic cell mediated by photodynamic therapy having the ability to suppress the growth of tumor - Google Patents

Autologous dendritic cell mediated by photodynamic therapy having the ability to suppress the growth of tumor Download PDF

Info

Publication number
WO2009008666A3
WO2009008666A3 PCT/KR2008/004042 KR2008004042W WO2009008666A3 WO 2009008666 A3 WO2009008666 A3 WO 2009008666A3 KR 2008004042 W KR2008004042 W KR 2008004042W WO 2009008666 A3 WO2009008666 A3 WO 2009008666A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
suppress
growth
photodynamic therapy
dendritic cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/004042
Other languages
French (fr)
Other versions
WO2009008666A2 (en
Inventor
Dae-Seog Lim
Ju-Ah Jeong
Hyun-Soo Lee
Yong-Soo Bae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CreaGene Inc
Original Assignee
CreaGene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CreaGene Inc filed Critical CreaGene Inc
Publication of WO2009008666A2 publication Critical patent/WO2009008666A2/en
Publication of WO2009008666A3 publication Critical patent/WO2009008666A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to mature dendritic cells (DCs) having the enhanced ability to induce anti-tumor immune responses, and to a method for the preparation of the above-mentioned DCs through the procedure of pulsing immature DCs with lysates of cancer cells on which photodynamic therapy (PDT) has been conducted. The dendritic cell of this invention acquires an activity to induce anti-tumor immune responses so that it exerts a remarkable effect to suppress the growth of tumor.
PCT/KR2008/004042 2007-07-09 2008-07-09 Autologous dendritic cell mediated by photodynamic therapy having the ability to suppress the growth of tumor Ceased WO2009008666A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070068524A KR100954315B1 (en) 2007-07-09 2007-07-09 Photodynamic therapy-mediated autologous dendritic cells with tumor growth inhibition
KR10-2007-0068524 2007-07-09

Publications (2)

Publication Number Publication Date
WO2009008666A2 WO2009008666A2 (en) 2009-01-15
WO2009008666A3 true WO2009008666A3 (en) 2009-03-19

Family

ID=40229274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/004042 Ceased WO2009008666A2 (en) 2007-07-09 2008-07-09 Autologous dendritic cell mediated by photodynamic therapy having the ability to suppress the growth of tumor

Country Status (2)

Country Link
KR (1) KR100954315B1 (en)
WO (1) WO2009008666A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071791A2 (en) 2008-12-17 2010-06-24 Discovery Technology International, Lllp Piezoelectric motor with high torque

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOLLNICK S.O. ET AL.: "Generation of effective antitumor vaccines using photodynamic therapy", CANCER RES., vol. 62, 2002, pages 1604 - 1608 *
GOMER C.J. ET AL.: "Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins", CANCER RES., vol. 56, 1996, pages 2355 - 2360 *

Also Published As

Publication number Publication date
KR20090005472A (en) 2009-01-14
WO2009008666A2 (en) 2009-01-15
KR100954315B1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
WO2010141738A3 (en) Compositions and method for inhibiting tumor growth
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
WO2021062227A3 (en) Compositions and methods for treatment of liquid cancers
WO2014028453A3 (en) Natural killer cells and uses thereof
SG170006A1 (en) Monoclonal antibodies against cd30 lacking fucosyl residues
WO2006089231A3 (en) Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
WO2014004427A8 (en) Anti-egfr antibodies and uses thereof
WO2007084672A3 (en) Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
HK1197071A1 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2010105728A3 (en) Active retinal implant
WO2011130566A3 (en) Method for treating solid tumors
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
WO2012086991A3 (en) Light therapy apparatus and method for controlling same
EP2095775A4 (en) Abnormal electrical conduction-blocking apparatus using photodynamic therapy (pdt)
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
WO2012020100A3 (en) Compositions and methods for producing dendritic cells
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
WO2009032256A3 (en) Apc activators in combination with a cytokine-secreting cell and methods of use thereof
WO2009008666A3 (en) Autologous dendritic cell mediated by photodynamic therapy having the ability to suppress the growth of tumor
WO2005046571A3 (en) Lactoferrin as an adjuvant in cancer vaccines
WO2008098183A3 (en) Combination therapy for treating cancer
MX357491B (en) Co-differentiation of monocytes from allogeneic donors.
GB2534478A (en) Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
EP3999527A4 (en) Methods and compositions for targeting tgf-beta signaling in cd4+ helper t cells for cancer immunotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08778702

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08778702

Country of ref document: EP

Kind code of ref document: A2